News - AstraZeneca, Xarelto

Filter

Current filters:

AstraZenecaXarelto

Popular Filters

1 to 25 of 385 results

Interview: AstraZeneca’s oncology expert Susan Galbraith on the company’s exciting pipeline

Interview: AstraZeneca’s oncology expert Susan Galbraith on the company’s exciting pipeline

11-04-2014

The full year report from Anglo-Swedish drug major AstraZeneca (LSE: AZN) in February was full of optimism.…

AstraZenecaInterviewsIressaOncologyPharmaceuticalUK

Starpharma expands accord with AstraZeneca

Starpharma expands accord with AstraZeneca

07-04-2014

Australian biotech firm Starpharma has signed a second, expanded agreement with Anglo-Swedish drug major…

AstraZenecaBiotechnologyOncologyResearchStarpharma

ACC 2014: Bayer presents new data for Xarelto and initiates new Phase III trials

ACC 2014: Bayer presents new data for Xarelto and initiates new Phase III trials

01-04-2014

German drug major Bayer presented new analyses from the pivotal ROCKET AF and EINSTEIN clinical trials…

BayerCardio-vascularJohnson & JohnsonPharmaceuticalResearchXarelto

AstraZeneca and MRC to create new discovery center in Cambridge

AstraZeneca and MRC to create new discovery center in Cambridge

31-03-2014

Anglo-Swedish drug major AstraZeneca and the UK Medical Research Council (MRC) have entered into a collaboration…

AstraZenecaNorthern EuropePharmaceuticalResearchUK

AstraZeneca acquires full control of Japanese subsidiary

AstraZeneca acquires full control of Japanese subsidiary

26-03-2014

Anglo-Swedish drug major AstraZeneca today announced the completion of the purchase of Sumitomo Chemical’s…

Asia-PacificAstraZenecaJapanMergers & AcquisitionsPharmaceutical

AstraZeneca unit debuts new open innovation platform for partnering programs

25-03-2014

Anglo-Swedish drug major AstraZeneca’s IMED Biotech unit has launched a dedicated web site to support…

AstraZenecaBiotechnologyResearch

Japanese approval for Forxiga and Lonsurf

24-03-2014

Anglo-Swedish drug major AstraZeneca says that Japanese Ministry of Health, Labor and Welfare approved…

Asia-PacificAstraZenecaDiabetesForxigaJapanLonsurfOncologyOno PharmaceuticalOtsukaPharmaceuticalRegulationTaiho Pharmaceutical

Bayer foresees 8% pa sales growth for pharma through 2016

Bayer foresees 8% pa sales growth for pharma through 2016

13-03-2014

Germany’s Bayer expects strong growth for its pharmaceutical business as a result of a number of new…

AdempasBayerEyleaFinancialPharmaceuticalStivargaXareltoXofigo

AstraZeneca’s diabetes drug Xigduo launched in UK

AstraZeneca’s diabetes drug Xigduo launched in UK

11-03-2014

Anglo-Swedish drug major AstraZeneca’s type 2 diabetes drug Xigduo is now available in the UK.

AstraZenecaDiabetesPharmaceuticalRegulationUKXigduo

AstraZeneca to establish cancer research program with Korea’s HIDI

AstraZeneca to establish cancer research program with Korea’s HIDI

07-03-2014

Anglo-Swedish pharma major AstraZeneca has signed a memorandum of understanding (MoU) with the South…

Asia-PacificAstraZenecaOncologyPharmaceuticalResearch

Amarin files suit against AstraZeneca over Epanova

Amarin files suit against AstraZeneca over Epanova

05-03-2014

US biotech firm Amarin revealed in a Stock Exchange Commission submission that it has filed a complaint…

AmarinAstraZenecaBiotechnologyCardio-vascularEpanovaLegalNorth AmericaOmthera PharmaceuticalsPatentsUSAVascepa

FDA approves Bydureon Pen for type 2 diabetes

FDA approves Bydureon Pen for type 2 diabetes

03-03-2014

Anglo-Swedish drug major AstraZeneca says the US Food and Drug Administration has approved the Bydureon…

AlkermesAmylinAstraZenecaBristol-Myers SquibbBydureonDiabetesPharmaceuticalRegulationUSA

FDA approves Myalept, the first drug to treat a rare metabolic disease

FDA approves Myalept, the first drug to treat a rare metabolic disease

26-02-2014

The US Food and Drug Administration has approved Myalept (metreleptin for injection) as replacement therapy…

AstraZenecaBristol-Myers SquibbmetreleptinMyaleptNorth AmericaPharmaceuticalRare diseasesRegulationUSA

Ardelyx licenses NaP2b to Sanofi in deal worth up to $198 million

Ardelyx licenses NaP2b to Sanofi in deal worth up to $198 million

25-02-2014

US venture-funded biopharmaceutical company Ardelyx has licensed its novel phosphate transport NaP2b…

ArdelyxAstraZenecaLicensingNaP2bNephrology and HepatologyPharmaceuticalSanofitenapanor

Positive CHMP opinion for Teva’s DuoResp Spiromax for asthma and COPD

22-02-2014

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive…

AstraZenecaDuoResp SpiromaxPharmaceuticalRegulationRespiratory and PulmonarySymbicortTeva Pharmaceutical Industries

Another FDA delay for Bayer/J&J’s Xarelto in ACS indication

Another FDA delay for Bayer/J&J’s Xarelto in ACS indication

14-02-2014

There was further negative news for Germany’s Bayer and partner US health care giant Johnson & Johnson,…

BayerCardio-vascularJanssenJohnson & JohnsonNorth AmericaPharmaceuticalRegulationUSAXarelto

FDA to review heart failure risk with AstraZeneca diabetes drug

FDA to review heart failure risk with AstraZeneca diabetes drug

12-02-2014

The US Food and Drug Administration has requested clinical trial data from Anglo-Swedish drug major AstraZeneca,…

AstraZenecaDiabetesKombiglyzeNorth AmericaOnglyzaPharmaceuticalRegulationResearchUSA

AstraZeneca 4th-qtr profits plunge 26% on generic woes

AstraZeneca 4th-qtr profits plunge 26% on generic woes

06-02-2014

Increasing generic competition took its toll on Anglo-Swedish drug major AstraZeneca, which this morning…

AstraZenecaFinancialPharmaceutical

UK’s NICE consults on updating guidance for Tarceva and Iressa

UK’s NICE consults on updating guidance for Tarceva and Iressa

04-02-2014

The UK’s National Institute for Health and Care Excellence (NICE) said this morning that it is reviewing…

AstraZenecadocetaxelIressaOncologyPharmaceuticalRegulationRocheTarcevaUK

Pharma multinationals facing more pricing problems in India

Pharma multinationals facing more pricing problems in India

03-02-2014

Even as a battle royal appears to be brewing between India's drug price regulator, the National Pharma…

Asia-PacificAstraZenecaFinancialGlaxoSmithKlineIndiaNovartisPfizerPharmaceuticalPricing

AstraZeneca in licensing deal for MALT1 inhibitors; closes Bangalore R&D site

AstraZeneca in licensing deal for MALT1 inhibitors; closes Bangalore R&D site

31-01-2014

Belgium-based VIB, a non-profit research institute in life sciences, and the Center for Drug Design and…

Asia-PacificAstraZenecaIndiaInflammatory diseasesOncologyPharmaceuticalResearchTropical diseases

Hutchison China MediTech upgraded by Panmure

30-01-2014

In a new report on Chinese pharmaceutical company Hutchison China MediTech, Panmure Gordon analyst Savvas…

AstraZenecaFinancialHutchison MediTechOncologyPharmaceuticalResearchvolitinib

1 to 25 of 385 results

Back to top